BioTuesdays

Tag - Michael Higgins

Tryp_Therapeutics
Markets

Ladenburg starts Tryp Therapeutics at buy; PT $2

Ladenburg Thalmann initiated coverage of Tryp Therapeutics (OTCQB:TRYPF; CSE:TRYP) with a “buy” rating and $2 price target. The stock closed at 37 cents on Aug. 25. Tryp is focused on developing psychedelic...

August 26, 2021
4D-Pharma-PLC
Markets

Ladenburg starts 4D Pharma at buy; PT $35

Ladenburg Thalmann launched coverage of 4D Pharma PLC (NASDAQ:LBPS) with a “buy” rating and $35 price target. The stock closed at $10.55 on May 12. 4D Pharma is a Leeds, UK-based biotechnology company developing live...

May 13, 2021
Catabasis Pharma
Markets

Ladenburg starts Catabasis Pharma at buy; PT $6

Ladenburg Thalmann launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and price target of $8. The stock closed at $1.78 on May 11. Catabasis is a Boston-based biotechnology company focused...

May 12, 2021
Artelo Biosciences Logo
Markets

Ladenburg starts Artelo Biosciences at buy; PT $7

Ladenburg Thalmann initiated coverage of Artelo Biosciences (NASDAQ:ARTL) with a “buy” rating and price target of $7. The stock closed at $1.63 on Feb. 11. Artelo is developing first-in-class, proprietary therapeutics...

February 12, 2021
Novavax Logo
Markets

Ladenburg ups Novavax PT to $24 from $16

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $24 from $16 after the company reported impressive pivotal results with its lead asset, NanoFlu. The stock closed at $12.77 on March 24. Analyst...

March 25, 2020
Marinus Pharma
Markets

Ladenburg starts Marinus Pharma at buy; PT $20

Ladenburg Thalmann launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with a “buy” rating and $20 price target. The stock closed at $6.74 on June 5. Marinus is developing ganaxolone (GNX), a synthetic analog of...

June 6, 2018
Flex Pharma
Markets

Ladenburg ups Flex Pharma PT to $20 from $13

Ladenburg Thalmann raised its price target for Flex Pharma (NASDAQ:FLKS) to $20 from $13 after the company announced that its lead asset, FLX-787, reduced the frequency of cramps/spasms in a 57-patient, placebo...

March 29, 2018